Amsalu Anteneh, Desta Kindie, Nigussie Demiss, Delelegne Demoze
Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar P.O.box 196, Ethiopia.
School of medicine, College of Medicine and Health Sciences, Hawassa University, Hawassa P.O.box 1560, Ethiopia.
Int J Ophthalmol. 2017 May 18;10(5):776-781. doi: 10.18240/ijo.2017.05.20. eCollection 2017.
To assess the pattern of ocular manifestation and associated factors among human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) patients on highly active antiretroviral therapy (HAART) at Hawassa University Referral Hospital, Southern Ethiopia.
A cross sectional study was conducted from January 2014 to April 2015. After obtaining informed written consent, 240 adult HIV/AIDS patients on HAART were randomly selected regardless of their ophthalmic symptoms, WHO status or CD4 count. Data were collected using structured questionnaires and ophthalmologic clinical examination. Data were entered and analyzed using SPSS version 20.0 software.
The mean duration of HAART was 62.5mo. The prevalence of HIV related ocular manifestation was 14.2%. Seborrheic blepharitis (5%) was the most common ocular manifestation, followed by squamoid conjunctival growth (3.8%). The rate of ocular manifestation was significantly higher among study participants who had CD4+ count <200 cells/µL (AOR=3.83; 95%CI: 1.315-11.153), low duration of HAART (AOR=3.0; 95%CI: 1.305-6.891) and who had primary school education [odds ratio (OR) =2.8; 95%CI: 1.105-7.099]. Prevalence of visual impairment and blindness was 10.9% and 5.8%, respectively.
HAART may be the reason for the decline in the prevalence of ocular manifestation in HIV/AIDS patients in the study area. Ophthalmologic screening of HIV/AIDS patients, especially those with CD4 counts of <200/µL cells and in the first five years of HAART follow-up is recommended to reduce visual impairment and/or blindness.
评估埃塞俄比亚南部哈瓦萨大学转诊医院接受高效抗逆转录病毒治疗(HAART)的人类免疫缺陷病毒(HIV)/获得性免疫缺陷综合征(AIDS)患者的眼部表现模式及相关因素。
于2014年1月至2015年4月进行了一项横断面研究。在获得知情书面同意后,随机选取240例接受HAART的成年HIV/AIDS患者,无论其有无眼部症状、世界卫生组织(WHO)状态或CD4细胞计数情况。通过结构化问卷和眼科临床检查收集数据。使用SPSS 20.0软件录入和分析数据。
HAART的平均疗程为62.5个月。HIV相关眼部表现的患病率为14.2%。脂溢性睑缘炎(5%)是最常见的眼部表现,其次是鳞状结膜生长(3.8%)。CD4+细胞计数<200个/微升的研究参与者(调整后比值比[AOR]=3.83;95%置信区间[CI]:1.315 - 11.153)、HAART疗程短(AOR=3.0;95%CI:1.305 - 6.891)以及接受小学教育的参与者[比值比(OR)=2.8;95%CI:1.105 - 7.099]的眼部表现发生率显著更高。视力损害和失明的患病率分别为10.9%和5.8%。
HAART可能是研究地区HIV/AIDS患者眼部表现患病率下降的原因。建议对HIV/AIDS患者进行眼科筛查,尤其是CD4细胞计数<200/微升细胞的患者以及HAART随访的前五年患者,以减少视力损害和/或失明。